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CME ARTICLE
Cutaneous Lymphomas: An Update. Part 1: T-Cell and
Natural Killer/T-Cell Lymphomas and Related Conditions
Werner Kempf, MD,*† Dmitry V. Kazakov, MD, PhD,‡ and Katrin Kerl, MD§
Abstract: Primary cutaneous T-cell lymphomas (CTCL) represent
the majority of cutaneous lymphomas (CLs) and are a spectrum of
diseases with a wide variety of clinical, histological, and phenotypic
features and diverse biologic behavior. This review focuses on the
observations on new variants of CTCL and recent developments in
deciphering the pathogenetic mechanisms, which have implication
for the nosologic concepts and future classiﬁcation of CLs. Variants
of mycosis fungoides (MF) such as the unilesional and the papular
form have been characterized in more detail. Studies analyzed the
expression of CD30 and PD-1 in MF and other forms of CTCL.
New variants in the group of cutaneous CD30+ lymphoproliferative
disorders include the epidermotropic CD8+ variant of lymphoma-
toid papulosis (type D) and angiocentric lymphomatoid papulosis
(type E), which histologically mimic aggressive lymphomas, and
therefore may be diagnostically challenging. Cutaneous prolifera-
tions of T cell–expressing markers of follicular helper T cells (PD-1,
CXCL-13, and bcl-6) display a prognostically heterogeneous group.
There is an increasing spectrum of CTCL with the expression of
CD8 by tumor cells, including CD8+ MF, CD8+ forms of cutaneous
CD30+ lymphoproliferative disorders, and CD8+ small/medium-
sized lymphoproliferations, which are not included as distinct enti-
ties in the World Health Organization–European Organization for
Research and Treatment of Cancer for CLs and the World Health
Organization classiﬁcation. Unusual presentations and incomplete
phenotypes of blastic neoplasm of plasmacytoid dendritic cells are
discussed. Clinicopathologic correlation is mandatory for the diag-
nosis of primary CLs. Analysis of genetic and epigenetic alterations
in CLs revealed new diagnostic markers and putative targets for
therapy of aggressive forms of CLs.
Key Words: cutaneous lymphoma, lymphoproliferation, genetics,
diagnosis, WHO, classiﬁcation, CD8, small/medium sized, lympho-
matoid papulosis
(Am J Dermatopathol 2014;36:105–123)
LEARNING OBJECTIVES
After completing this CME activity, physicians should
be better able to:
1. Describe the morphologic and phenotypic spectrum of
cutaneous T-cell lymphomas.
2. Identify new variants of cutaneous T-cell lymphomas,
especially in mycosis fungoides and cutaneous CD30-
positive lymphoproliferative disorders.
3. Distinguish indolent forms of cutaneous T-cell lymphomas
from aggressive forms.
INTRODUCTION
Primary cutaneous lymphomas (CLs) are the second
most common form of extranodal non-Hodgkin lymphomas
(NHL) and represent a heterogeneous group of neoplasms
with a wide spectrum of clinical, histological, and immuno-
phenotypical features1,2 (Table 1). The histological examina-
tion plays a crucial role and is often the starting point in the
diagnostic work-up of CL. It encompasses immunophenotyp-
ing and in some CL also molecular genetic analyses. Almost
all the diagnostic tests can nowadays be performed on forma-
lin-ﬁxed and parafﬁn-embedded tissues and thus became
widely used. Terminology of CL should follow the current
World Health Organization (WHO) classiﬁcation (fourth edi-
tion, 2008), which is accepted by both hematopathologists and
dermatopathologists.3 The WHO classiﬁcation integrated the
unique biologic features of CL as they were described in the
WHO–European Organization for Research and Treatment of
Cancer (EORTC) classiﬁcation for primary CL into a classiﬁ-
cation of tumors of hematopoietic and lymphoid tissues.3 Both
the WHO-EORTC classiﬁcation (2005) and the current WHO
classiﬁcation (2008) follow the concept of deﬁning lympho-
mas by their clinical, histological, immunophenotypic, and
genetic features and the site of primary presentation in a mul-
tiparameter approach as it had been originally introduced by
the Revised European American Lymphoma classiﬁcation.4,5
As a consequence, the clinical manifestation is emphasized as
an essential element in the diagnostic approach for primary
CL. The diagnosis in primary CL can therefore only be
achieved by an integration of clinical, histological, immuno-
phenotypic, and genetic ﬁndings in the context of a clinico-
pathologic correlation.
CUTANEOUS T-CELL LYMPHOMAS
Mycosis fungoides (MF) is the most common form of
primary CL accounting for approximately 40% of all CL.
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According to the WHO-EORTC and the WHO classiﬁcations,
MF is deﬁned by its classic form, that is, by patches and
plaques, or variants showing a similar course.1–3
Diagnosis of early MF remains one of the challenging
aspects of the disease because histological ﬁndings are subtle
with less prominent or even lacking atypia of lymphocytes,
interface changes with vacuolization, lining-up of lympho-
cytes along the junctional zone.6 A T-cell clone is only found
in half of the biopsies in early disease stages. Thus, neither
molecular tests for T-cell clonality nor phenotypic marker are
of signiﬁcant diagnostic value in early MF. Thus, clinical
features are very important for the diagnosis. Using high-
throughput genomic transcription proﬁling, Zhang et al7 iden-
tiﬁed 19 genes with speciﬁc enrichment in early MF lesions
that showed no signiﬁcant upregulation in chronic dermatitis.
Among the 19 genes, TOX and PDCD1 discriminated
between early MF lesions and biopsies from inﬂammatory
skin disorders by RNA expression. TOX demonstrated
highly speciﬁc staining of MF cells in early MF biopsies in
immunohistochemistry.7 These data need to be conﬁrmed in
larger studies.
MF exhibits a broad and increasing spectrum of clinical,
histological, and immunophenotypic variants.8 Among those,
unilesional, folliculotropic, and granulomatous variants exhibit
a different course and prognosis. In contrast to classic MF in
patch and plaque stages with a 5-year survival rate of more
than 90%, follicular or folliculotropic MF and granulomatous
MF carry an impaired prognosis with 5-year survival rates of
approximately 60% and 41% by 15 years9–12.
Clinically, folliculotropic MF usually presents with
patches and plaques and hair loss within the lesions.
Occasionally, the disease may manifest with predominantly
papular lesions (Fig. 1). Recently, an unusual clinical
presentation with alopecia areata-like patchy lesions has been
described, which may be diagnostically misleading and seen
in up to a third of patients with MF-associated hair loss.13,14
One has to be aware that epidermotropism into the interfol-
licular epidermis, which is a useful diagnostic ﬁnding for
classic MF, is absent in 40%–60% of folliculotropic MF.15
In approximately 70% of biopsies, folliculotropic MF is
accompanied by follicular mucinosis (Fig. 2), but the latter
may be completely absent in the remaining cases15 (Fig. 3).
Distinction of folliculotropic MF-associated follicular muci-
nosis from benign (idiopathic) follicular mucinosis remains
challenging. Although folliculotropic MF more probably dis-
plays a dense lymphocytic inﬁltrate with slight nuclear atypia,
an increased CD4/CD8 ratio and a clonal rearrangement of
T-cell receptor (TCR) genes, the histological or phenotypic
features do not allow separating the 2 entities with certainty.16
In 2011, Magro et al17 described a series of patients with facial
TABLE 1. WHO Classification for Lymphoid Neoplasms
(Fourth Edition, 2008)*
Mature T-cell and NK-cell neoplasms
Mycosis fungoides
MF variants and subtypes
Folliculotropic MF
Pagetoid reticulosis
Granulomatous Slack Skin
Sézary Syndrome
Adult T-cell leukemia/lymphoma
Primary cutaneous CD30+ T-cell lymphoprociferative disorders
Primary cutaneous anaplastic large cell lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma†
Extranodal NK/T-cell lymphoma, nasal type
Primary cutaneous peripheral T-cell, rare subtypes
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell
lymphoma (provisional)
Primary cutaneous g/d T-cell lymphoma
Primary cutaneous CD4+ small/medium T-cell lymphoma (provisional)
Primary cutaneous peripheral T-cell, unspeciﬁed
*List restricted to CLs in the WHO classiﬁcation.
†Phenotype (by deﬁnition): TCR alpha/beta chain positive.
FIGURE 1. Folliculotropic MF: clinical manifestation with ery-
thematous papular lesions on the trunk.
FIGURE 2. Folliculotropic MF with infiltration of hair follicles
by small- to medium-sized lymphocytes and follicular muci-
nosis (magnification, ·100).
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erythematous papules resembling rosacea and/or nodules and
large scaly plaques that histolopathologically manifested folli-
culotropic inﬁltrates of small lymphocytes with cerebriform
nuclei, a CD4/CD8 ratio .5:1, reduced CD7 expression and
monoclonal T cells in 25% of the cases. The authors proposed
the term folliculotropic T-cell lymphocytosis for this condition
which in their opinion represents another manifestation of
T-cell dyscrasia.18 Further studies are needed to clarify whether
these cases represent folliculotropic MF or a reactive inﬂam-
matory process based on its indolent course with a median
duration of 3 years. Most recently, follicular mucinosis and
MF-like drug eruption has been described.19 Folliculotropic
MF must also be distinguished from rare cases of adult T-cell
leukemia/lymphoma accompanied by follicular mucinosis.20
Similar to folliculotropic MF, prognosis of granuloma-
tous MF with a 5-year survival of 66% is worse than in classic
MF and granulomatous slack skin (GSS).12 Histologically,
a sarcoid-like or, more rarely, a granuloma annulare–like pat-
tern is found.21 The neoplastic lymphocytes are small- to
medium-sized lymphocytes.12,21 Remarkably, epidermotrop-
ism is very subtle or absent in half of the biopsies that makes
the diagnosis challenging. Detection of T-cell clonality may
be a useful adjunctive diagnostic marker to separate granulo-
matous MF from sarcoidosis.22,23 Rare coexistence of patch
stage MF and interstitial granuloma annulare in the same
patient, however, may represent a diagnostic pitfall.24,25 A
granulomatous process can also be seen in follicullotropic
MF with lesions presenting with destruction of follicular units
and secondary granulomatous reaction.26
Due to overlapping histological features between
granulomatous MF and GSS, distinction relies on the clinical
presentation with development of bulky hanging skin folds in
GSS.12,21 Both in granulomatous MF and in GSS, there is
a signiﬁcantly increased risk of the development of a second
lymphoid neoplasm, particularly Hodgkin lymphoma, occur-
ring in 20%–50% of the patients.
In contrast to folliculotropic MF and granulomatous
MF, unilesional MF represents the other end of the prognostic
spectrum of MF with an excellent prognosis. Currently,
however, unilesional MF is not recognized as a speciﬁc sub-
type in the WHO classiﬁcation. A recent analysis of the lit-
erature identiﬁed approximately 130 cases of unilesional
MF.27 The mean age at diagnosis is 47 years, but patients
of any age group including children can be affected. Unile-
sional MF presents as a solitary patch, plaque, or nodule
mostly arising on the trunk or head and neck. Histologically,
unilesional MF displays the typical epidermotropic lympho-
cytic inﬁltrates as seen in patch and plaque stages of classic
MF. In a subset of cases, folliculotropic and syringotropic
inﬁltrates are found.28 Most cases display a CD4+ phenotype
and clonal T cells. Unilesional MF has an excellent prognosis.
Development of additional noncontiguous MF lesions during
course may occur but is the exception seen in only very few
patients.29 Recurrences after treatment (surgical excision and/
or radiotherapy) occur in 9% of the patients. Development of
tumor stage or transformation with large cells accounting for
more than 25% of the inﬁltrate has been reported including 2
patients with folliculotropic unilesional MF, but in general,
this evolution to tumor stage seems to be rare in unilesional
MF.30,31
Pagetoid reticulosis (PR), listed as MF subtype in both
WHO-EORTC and WHO classiﬁcations, shows a more prom-
inent epidermotropism and nuclear pleomorphism compared
with unilesional MF and more commonly displays a CD8+
phenotype.32 Furthermore, PR manifests more often as hyper-
keratotic lesions. Nevertheless, it can be debated whether the
historical term pagetoid reticulosis should be subsummarized
within unilesional MF in future classiﬁcations.
Papular MF is a peculiar clinical variant of MF
manifesting with papules, but not with patches or plaques.33,34
However, the latter may arise later in the course of the dis-
ease. Like in other MF forms, histology of papular MF shows
epidermotropic inﬁltrates of small atypical lymphocytes,
which may justify considering this clinically very unusual
form within the spectrum of MF. Distinction from lympho-
matoid papulosis (LYP) type B, which histologically also
shows epidermotropic inﬁltrates of small CD4+ and often
CD302 lymphocytes, depends on clinical features. In papular
MF, the lesions persist, whereas a waxing and waning with
spontaneous regression of the lesions after a few weeks is
observed in LYP.
MF is a neoplasm of lymphoid cells with a CD4+
T-helper (TH) phenotype and a shift from TH1 cytokines in
early stages of the disease to a TH2 cytokine pattern in late
stage.35 Various phenotypes of otherwise typical MF has been
described including CD8+ MF, which often presents with
hyper- or hypopigmented patches and plaques or CD56+
MF.8,36 Rarely, a CD4/CD8 double-negative phenotype has
been observed that more frequently seems to be associated
with an unusual clinical presentation such as annular MF.37,38
Remarkably, CD4/CD8 double-negative MF expresses PD-1,
a marker of follicular helper T cells in certain cases.38 This
feature may be of therapeutic relevance in the future because
PD-1 may serve as a therapeutic target.
Most phenotypic MF variants seem to have no prognos-
tic impact.39 Recently, Edinger et al,40 however, demonstrated
that the expression of CD30 by intradermal lymphocytes and
a high proliferation rate in patch and plaque stage MF are
FIGURE 3. Folliculotropic MF without follicular mucinosis.
Note the subtle epidermotropism (magnification, ·100).
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linked to an impaired prognosis. In contrast, the expression of
CD30 in tumor stage is an independent marker for a better
disease-related survival.41 Based on these data expression of
CD30 should be examined in all stages of MF.
Progression of MF into tumor stage characterized by
large and often ulcerated nodules occurs in only a subset of
patients (10%–20%).9 It should be distinguished from trans-
formation histologically deﬁned by the occurrence of large
pleomorphic cells accounting for more than 25% of the lym-
phocytes.42 Large cell transformation in MF is usually asso-
ciated with an aggressive clinical course and poor survival,
requiring aggressive therapeutic approach. To identify prognos-
tic factors, Benner et al have recently analyzed the prognostic
relevance of clinical, histological, and immunophenotypical
features in a large cohort of transformed MF patients. Mul-
tivariate analysis of 75 patients with only skin lesions at the
time of large cell transformation was performed and CD30
negativity, folliculotropic MF and extent of skin lesions
were found to be independent parameters for both disease-
speciﬁc survival and overall survival.41 Increased Twist
expression has been found in advanced stages of MF, sug-
gesting that increased Twist expression may correlate with
tumor progression.43
Tumor stage MF carries a characteristic molecular sig-
nature reﬂecting the high proliferative activity of the T cells,
including altered expression of cell cycle and kinetochore
regulators.44 In addition, the molecular signature in MF tumor
stage suggests that MF originates from interleukin 32–produc-
ing cells.44 Furthermore, previously unreported therapeutic
targets and/or diagnostic markers such as GTSF1 and TRIP13
were identiﬁed. Array comparative genomic hybridization re-
vealed gains in myc gene and losses in CDKN2A, CDKN2B,
and MTAP genes. Patients with tumors harboring more than 5
DNA aberrations (so-called unstable group) had a shorter
overall survival.45 The prognostic relevance of inactivation
of the CDKN2A–CDKN2B was conﬁrmed by Laharanne
et al46 who found a shorter survival in patients with trans-
formed MF with deletion of this locus.
Se´zary Syndrome
Sézary syndrome (SS) is a rare form of cutaneous T-cell
lymphomas (CTCL) accounting for 3% of all CL. In contrast to
MF, SS carries an unfavorable prognosis with a median sur-
vival of less than 3 years.47–49 Several lines of evidence from
molecular genetic studies support the concept that SS is differ-
ent from MF and not only a leukemic form of MF.50 It turned
out that SS and MF arise from distinct T-cell subsets. T cells in
SS express the lymph node homing molecules CCR7 and
L-selectin and the differentiation marker CD27, a phenotype
consistent with central memory T cells. T cells isolated from
MF skin lesions lack CCR7/L-selectin and CD27 but strongly
expressed CCR4 and CLA, a phenotype suggestive of skin
resident effector memory T cells.51 Genome-wide analysis of
MF and SS also revealed different chromosomal gain and los-
ses in the two diseases.52 Although the histological features in
SS in general are very similar to those seen in MF patch and
plaque stages, the inﬁltrate in SS appears more monotonous.
Unspeciﬁc features with only very subtle epidermotropism of
atypical lymphocytes are found in up to 40% of the biopsies,
which makes the histological assessment of SS challenging53
(Figs. 4 and 5). In some cases, folliculotropic inﬁltrates have
been observed. In some cases of SS, the biopsy tends to show
more spongiotic features sometimes with eosinophils rarely
seen in MF and less of the more common MF typical ﬁndings
like prominent reticular ﬁbroplasia and Pautrier collections. In
addition to the most common CD4+ phenotype, a majority of
T cells in SS express PD-1.54 Because this marker is also
expressed by MF in variable degree, it does not serve as
FIGURE 4. SS: band-like dense lymphocytic infiltrate in the
upper demis (magnification, ·20).
FIGURE 5. SS: perivascular and interstitial infiltrate of small
lymphocytes and exocytosis of only very few lymphocytes
(magnification, ·200).
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a helpful diagnostic marker. The clinical features and the pres-
ence of more than 1000 cerebriform cells per milliliter periph-
eral blood are essential for the diagnosis of SS. There are
sporadic reports on nonerythrodermic manifestation of SS
including papular forms.55
Despite the achievements from molecular studies, the
distinction of SS from erythrodermic inﬂammatory disorders
remains a differential diagnostic problem.56 With the excep-
tion of atypical lymphocytes, the moderate to high density of
dermal inﬁltrates and Pautrier microabscesses, which are
almost only found in SS, no morphologic parameter was
found to be speciﬁc of erythrodermic forms of CTCL encom-
passing SS and erythrodermic MF. Single lymphocytes exo-
cytosis, telangiectasias, and a more subtle lymphocytic dermal
inﬁltrate were signiﬁcantly more frequent in erythrodermic
inﬂammatory conditions. A low (,10%) CD8:CD3 ratio in
the epidermal lymphocytic inﬁltrate and dermal CD30+ lym-
phocytes were signiﬁcantly more frequent in CTCL.56 In sum-
mary, a correct differential diagnosis between SS and an
erythrodermic inﬂammatory dermatosis was achieved with
certainty only in 57% of cases. The distinction of late-onset
atopic dermatitis, red man syndrome, and pre-SS from initial
SS is difﬁcult due to overlapping clinical and histological
features, hindered by the unspeciﬁc histology in up to 40%
of SS biopsies, lack of widely accepted diagnostic criteria for
red man syndrome, and pre-SS. Repeated biopsies are useful
to increase the diagnostic accuracy.57,58 Progression of adult-
onset atopic dermatitis-like condition to overt SS in patients
under immunosuppressive therapy may support the concept
of pre-SS as a long-lasting premalignant condition, which may
develop to full-blown SS in a state of immunosuppression.59
Micro-RNAs are small noncoding RNAs controlling
gene expression. Five micro-RNA identiﬁed by microarray-
based analysis distinguish CTCL from inﬂammatory skin
disorders with an accuracy of more than 90%.60 Micro-RNA
represents targets for future therapeutic approaches. Among
them, miR-21 is upregulated and involved in apoptosis resis-
tance. Stimulation of Sézary cells or healthy CD4+ T cells
with interleukin-21 results in a strong activation of signal
transducer and activator of transcription 3, which is constitu-
tively activated in SS, and subsequent upregulation of miR-21
expression.61
Primary Cutaneous CD30+
Lymphoproliferative Disorders
Primary cutaneous CD30+ lymphoproliferative disorders
(CD30+ LPDs) are the second most common form (20%–25%)
of cutaneous T-cell lymphoma (CTCL).1,62 Primary cutaneous
CD30+ LPDs represent a spectrum of diseases including LYP,
primary cutaneous anaplastic large cell lymphoma (ALCL),
and so-called borderline cases.
LYP is a chronic, recurrent, and self-healing papulone-
crotic or papulonodular skin eruption. Traditionally, 3 histo-
logical types are distinguished: LYP type A with scattered or
grouped CD30+ large pleomorphic or anaplastic lymphoid cells
in the background of neutrophils and eosinophils, an epider-
motropic inﬁltrate of small lymphocytes (type B) (Fig. 6) or
cohesive sheets of atypical lymphoid cells with only a few
admixed reactive cells (type C). Individual lesions may show
overlapping features.63 Furthermore, different lesions in the
same patient may display different histological types. Recently,
2 new types (types D and E) have been described. Type D
shows epidermotropic inﬁltrates of CD8+ and CD30+ atypical
cells and mimics primary cutaneous aggressive epidermotropic
CD8+ cytotoxic T-cell lymphoma.64,65 We have described an
angioinvasive form of LYP that manifests with rapidly evolv-
ing eschar-like ulcers (Fig. 7)—usually few at a given time—
and angioinvasive inﬁltrates of CD30+ and often CD8+
medium-sized atypical lymphocytes (Fig. 8).66 For this type,
we propose the designation LYP type E. It represents a diag-
nostic pitfall by simulating aggressive lymphomas such as
extranodal natural killer (NK)/T-cell lymphoma. Nevertheless,
the lesions in LYP type E undergo spontaneous regression
within a few weeks like in other LYP types. Thus, aggressive
FIGURE 6. LYP (type B): epidermotropism of small-sized and
a few medium-sized atypical lymphocytes. Absence of large
anaplastic cells (magnification, ·200).
FIGURE 7. LYP (type E): eschar-like ulcer in the angioinvasive
variant.
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treatment should be avoided according to the recommendations
for the management of CD30+ LPD.67
Rare histopathological variants of LYP include syringo-
tropic, granulomatous, and follicular (reviewed in Kempf68).
Perieccrine inﬁltrates sometimes with effacement of the eccrine
units are seen in syringotropic LYP. Noncaseating granulomas
are a feature of granulomatous LYP. In so-called follicular
LYP, any combination of the following features can be seen:
perifollicular distribution of the inﬁltrate, intrafollicular CD30+
cells, cystic dilatation of a hair follicle, rupture of hair follicles,
hyperplasia of the follicular epithelium, follicular mucinosis,
and neutrophils collection in the follicular epithelium. The lat-
ter feature accounts for pustular lesions observed clinically in
these patients.69
There is a steadily increasing number of inﬂammatory
and infectious disorders and neoplasms that contain a signif-
icant number of CD30+ and sometimes atypical lymphocytes
and thus mimic LYP clinically and/or histologically.68,70,71
CD30+ pityriasis lichenoides et varioliformis (PLEVA) histo-
logically simulates LYP and other lymphomas.72 Careful clin-
icopathologic correlation allows separating CD30+ PLEVA
from LYP. Nevertheless, the overlap in histological and phe-
notypic and genotypic features suggests that these 2 disorders
may be more closely related than traditional concepts hold.72,73
Benign atypical intravascular CD30+ T-cell proliferation due to
trauma or inﬂammation represents a reactive condition mim-
icking intravascular lymphoma.74,75 This should be distin-
guished from the rare intravascular form of CD30+ ALCL.76
LYP persists usually for years or even decades but is not
associated with mortality. Nevertheless, patients suffering from
LYP should be monitored lifelong because about 25% of the
patients develop a second lymphoma, in particular Hodgkin
lymphoma, MF, and primary or nodal ALCL. In addition to the
expression of fascin by CD30+ cells in LYP, monoclonal TCR
gene rearrangement or diagnosis of LYP with histological
mixed type may be prognostic indicators of disease more prone
to develop those LYP-associated lymphomas.77,78
Primary cutaneous CD30+ ALCL most commonly pres-
ents clinically with solitary nodules or tumors and on histology
exhibits nodular cohesive inﬁltrates of large pleomorphic, ana-
plastic, or immunoblastic tumor cells.1,62 By deﬁnition, more
than 75% of the tumor cells express CD30.1 Rare morphologic
variants include angioinvasive, neutrophil-rich, histiocyte-rich,
and sarcomatoid forms.79–81 Neutrophil-rich CD30+ has been
referred to as pyogenic lymphoma.79 A predilection of young
patients has been found, with 10% of the patients experiencing
extracutaneous disease progression and 18% of the patients
dead at 10 months.82 The association of pyogenic ALCL with
immunesuppression and poor outcome should be validated in
further studies. Few cases of intravascular CD30+ ALCL have
recently been reported, including primary skin disease and
systemic lymphoma with secondary skin involvement.83,84
Most recently, a myxoid variant of ALCL has been
described.85
The most common phenotype in primary cutaneous
ALCL is that of a CD4+ T-helper phenotype. In rare cases,
tumor cells express CD8+ that seems not to be associated with
an impaired prognosis.86 By deﬁnition, more than 75% of the
tumor cells express CD30. In contrast to nodal ALCL, which
expresses ALK in approximately 60% of the cases, primary
cutaneous ALCL are usually negative for this marker and lack
the translocation t(2;5).62 Unusual cases of ALK+ primary
cutaneous ALCL, however, have been reported that are asso-
ciated with a translocation variant and cytoplasmic staining
for ALK.87 These rare cases may run a more aggressive
course and should most probably be treated similar to sys-
temic ALCL and could be suitable for treatment with the
ALK inhibitor Crizotinib.88
No phenotypic marker has been conﬁrmed to allow
distinction between LYP and ALCL. In a study on the
expression of chemokines receptors, expression of CXCR3
was found in a majority of LYP cases but in none of the 4
ALCL cases.89 These data still need to be conﬁrmed.
CD30+ LPD may involve or be restricted to mucosal
sites, particularly the oral cavity, orbit/conjunctiva, or nasal
cavity/sinuses.90,91 Similar cases have previously been
reported as traumatic ulcerative granuloma with stromal
eosinophilia.92 Sciallis et al91 referred to this condition as
mucosal CD30+ T-cell lymphoproliferations of the head and
neck and demonstrated that some of the lesions show a clin-
icopathologic spectrum similar to cutaneous CD30+ T-cell
LPDs. Histological features resembled primary cutaneous
ALCL accompanied in the majority of the cases by a variable
number of eosinophils. Patients with mucosal or mucocuta-
neous disease only have a favorable prognosis and none
developed systemic spread. Two cases in that series revealed
rearrangements of the DUSP22-IRF4 locus on chromosome
6p25.3, detected most frequently in primary cutaneous ALCL.93
Genetic analysis of primary cutaneous ALCL showed
gains on chromosomes 7q and 17q and losses on 6q and 13q.
Peripheral T-cell lymphoma, not otherwise speciﬁed (PTL),
NOS similarly showed gains on 7q and 17q but was dis-
tinguished by gains on chromosome 8 and loss of a focal
overlapping region on 9p21.94 Moreover, the study demon-
strated higher expression of the skin-homing chemokine
receptor genes CCR10 and CCR8 was found, which may
FIGURE 8. LYP (type E): angiocentric infiltrates with medium-
sized to large-sized lymphocytic cells within the vessel wall.
Magnification X200.
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contribute the lower tendency to disseminate to extracutane-
ous sites compared with more aggressive PTL, unspeciﬁed.
Subcutaneous Panniculitis-Like
T-Cell Lymphoma
This lymphoma accounts for 1% of all CL and for 75%
of all subcutaneous forms of T-cell lymphomas. In the WHO-
EORTC classiﬁcation and the WHO classiﬁcation (fourth
edition, 2008), this term is by deﬁnition restricted to cases
expressing a TCR alpha/beta phenotype.1,3 Therefore, dem-
onstration of expression of beta F1 (TCR alpha/beta) by
immunohistochemistry is a pivotal diagnostic marker for this
entity. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
displays an inﬁltration pattern reminiscent of lobular pannicu-
litis but is composed of small- to medium-sized lymphoid cells
having slightly to moderate nuclear pleomorphism. The rim-
ming of adipocytes by tumor cells is not disease speciﬁc and
has also been shown to occur in lupus panniculitis, which is
one of the major differential diagnoses. Karyorrhexis and
cytophagocytosis may be present.
Immunohistochemically, SPTCL expresses CD3+ CD42
CD8+ CD562, TIA-1+, granzyme B+, and beta F1+.95 SPTCL
is associated with a good prognosis with 5-year survival rate of
80%.95 Tumor spread to other tissues is rare. This is in striking
contrast to cells in subcutaneous lymphoma with a g/d-positive
TCR phenotype, which may involve the subcutaneous tissue,
and should therefore be considered in the differential diagnosis
(see below). The g/d-positive form has an unfavorable prog-
nosis.95,96 Clues to g/d-positive T-cell lymphoma include
angiocentric growth, involvement of the dermis and even an
epidermotropic component of the inﬁltrate, tumor cells with
hyperchromatic nuclei, and the expression of CD56 and in
particular TCR gamma. Extranodal T/NK-cell lymphoma,
which may present with subcutaneous involvement, has to be
considered as differential diagnosis. Demonstration of Epstein–
Barr virus (EBV) by in situ hybridization is useful in discrim-
inating this disease from SPTCL.
Due to overlapping features, relationship between lupus
profundus panniculitis and SPTCL has been a subject of
recent studies. Distinction between the 2 entities may be
difﬁcult, leading to the suggestion that they may belong to
a spectrum of disease.97,98 Most useful histopathological cri-
teria for distinguishing lupus panniculitis from SPTCL
included epidermal changes, lymphoid follicles with reactive
germinal centers, clusters of B cells, and mixed cell inﬁltrate
with prominent plasma cells.99 A considerable admixture of
plasma cells was found in SPTCL with concurrent or prior
diagnosis of lupus erythematosus, which was not observed in
the other cases of SPTCL.95 Borreliosis manifesting as lobular
panniculitis, represents a diagnostic pitfall, because the high
number of CD8+ lymphocytes mimics SPTCL. Moreover the
plasma cells and mucin deposition and clusters of CD123+
plasmacytoid dendritic cells simulate lupus panniculitis.100
Cutaneous Peripheral T-Cell Lymphoma,
Rare Subtypes
Both in the WHO-EORTC classiﬁcation and in the WHO
classiﬁcation, 3 lymphoma entities have been listed as
provisional rare subtypes of PTL based on their characteristic
clinicopathological, immunophenotypic, and prognostic fea-
tures and have been separated out from PTL, unspeciﬁed: (1)
primary cutaneous CD4+ small/medium T-cell lymphoma
(CD4+ SMTL), (2) primary cutaneous CD8+ aggressive epider-
motropic T-cell lymphoma (CD8+ AECTCL), and (3) primary
cutaneous gamma/delta T-cell lymphoma (CGD-TCL).1–3,101
Primary Cutaneous CD4+ Small/medium
T-Cell Lymphoma
CD4+ SMTL is listed as a provisional entity within the
group of PTL in both the WHO classiﬁcation (2008, fourth
edition) and the WHO-EORTC classiﬁcation. The relation-
ship of CD4+ SMTL to nodular T-cell pseudolymphoma
and its terminology are a matter of debate and has been pre-
viously reviewed.102 Although CD4+ SMTL was originally
considered a rare form of CTCL, it turned out that this lym-
phoproliferation is in fact much more common.103 The most
frequent clinical manifestation, which is observed in 75% of
the patients, is an nonulcerated nodule arising on the head and
neck area, especially on the face, and measuring up to 3 cm in
diameter.103 In a subset of patients, multiple nodules arise at
different body regions. In contrast to MF, the nodules develop
without preceding patches and plaques. Histologically, there
are dense nodular inﬁltrates predominantly composed of
small- and medium-sized lymphocytes, which display chro-
matin-dense nuclei with slight to moderate nuclear pleomor-
phism and a small cytoplasmic rim (Figs. 9 and 10).103
Epidermotropism may be focally present, but it is not a prom-
inent feature. Folliculotropism can occasionally be seen.
There is an admixture of eosinophils, small clusters of plasma
cells, and a variable number of macrophages occasionally form-
ing small nonnecrotizing granulomas. Immunohistochemistry
reveals expression of CD3 and CD4 by nearly all small- and
medium-sized lymphocytes. There is a remarkably high number
of CD20+ B cells, which are found in all cases, and may be
present in aggregations. In a subset of cases, a few scattered
CD30+ pleomorphic large lymphocytes (24%) are present. The
proliferation rate ranges from 5% to 30%.54,103 A monoclonal
rearrangement of the TCR gamma gene is found in at least 60%
of the cases.103 Recent studies have indicated that CD4+ SMTL
FIGURE 9. Primary cutaneous CD4+ SMTL: Proliferation with
dense nodular lymphocytic infiltrate. Magnification X20.
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represents a neoplastic proliferation of follicular T-helper (TFH)
cells based on the expression of CXCL-13 and PD-1.104
Due to a signiﬁcant overlap of clinical and histological
features, nodular T-cell pseudolymphoma and so-called
pseudolymphomatous folliculitis are the most challenging
differential diagnoses.54,105 Neither the composition of the
inﬁltrate nor the cytomorphology of the lymphocytes allow
differentiating between CD4+ SMTL and nodular T-cell pseu-
dolymphoma. Detection of clonal T cells has been reported in
both disorders and therefore does not serve as a reliable dis-
criminating diagnostic marker. In addition, PD-1 expression
has recently been described in all cases of CD4+ SMTL and in
nodular T-PSL.54 Based on the overlap in clinical, histologi-
cal, and phenotypic markers, some experts support the con-
cept that most cases classiﬁed as CD4+ SMTL are identical to
nodular T-PSL, at least when presenting as a solitary lesion.54
As a consequence, the term “cutaneous nodular proliferation
of pleomorphic T-lymphocytes of undetermined signiﬁ-
cance”103 or “primary cutaneous CD4+ small/medium-sized
T-cell proliferation” (R. Willemze, MD, PhD personal com-
munication, October 2011) were proposed.
The prognosis of CD4+ SMTL in its solitary or localized
form reported so far in the literature is excellent with 5-year
survival rates exceeding 90%.103,106,107 A subset of patients
with CD4+ SMTL present with rapidly evolving large tumors
or nodules, a higher proliferation rate of tumor cells, and a
lower number of inﬁltrating CD8+ cells. These patients carry
an impaired prognosis.107 In patients with solitary or localized
lesions, surgical excision and/or radiotherapy is the ﬁrst-line
therapy, whereas patients with multifocal lesions should be
treated more intensively by chemotherapy.
Remarkably, nodular lymphoproliferations composed
of CD8+ small- to medium-sized T cells have been
reported,108–111 which are composed of dense nodular inﬁl-
trates of small and occasionally medium-sized lymphoid cells
(Figs. 11 and 12). These lymphoproliferations occur not
only on the ear and on the face but also in extrafacial sites,
especially on the legs. The CD8+ SMTL not only has a similar
architecture and composition as the CD4+ SMTL but also
share biologic features of CD4+ SMTL with a favorable prog-
nosis when manifestating with a solitary lesion.108–111 These
data suggest that there is a phenotypically (CD4+ or CD8+)
heterogeneous group of small- to medium-sized LPDs, which
share clinical, histological, and prognostic features. For this
group, we propose the term primary cutaneous small- to
medium-sized LPDs (CD4+ or CD8+).102,111
Recently, Battistella et al112 described primary cutane-
ous follicular helper T-cell lymphoma as a new subtype of
CTCL based on the expression of follicular helper T-cell
(TFH) markers (CD10, Bcl-6, PD-1, CXCL-13, and ICOS)
by tumor cells. In 4 of 5 patients, the disease manifested with
multiple papules, plaques, and nodules predominantly on the
trunk and the head. In contrast to CD4+ SMTL, primary cuta-
neous follicular helper T-cell lymphoma usually presents with
multiple lesions and the inﬁltrates are mostly composed of
medium- to large-sized atypical T cells. The disease was
resistant to multiagent chemotherapy in patients with multi-
focal lesions. Gammon and Guitart113 have reported 3 patients
with rapidly evolving intertriginous tumoral lesions of non-
epidermotropic inﬁltrates of medium-sized T cells with
expression of follicular helper T cells. The authors referred
to the ﬁndings as intertriginous MFs. In regard to the absence
of preceding patches and the ﬁnding of nonepidermotropic
inﬁltrates, we consider this CTCL to be related to the recently
described follicular helper T-cell lymphomas. Further studies
are needed to clarify the relationship of this newly proposed
CTCL to CD4+ SMTL with which it shares some histological
and phenotypic features.
FIGURE 10. Primary cutaneous CD4+ SMTL/proliferation with
small- to medium-sized lymphocytes with chromatin-dense
nuclei and nuclear pleomorphism. Magnification X400.
FIGURE 11. Primary cutaneous CD8+ small/medium-sized
lymphoproliferative disorder: dense dermal lymphocytic
infiltrates of small- to medium-sized lymphocytes (magnifi-
cation, ·20).
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Primary Cutaneous CD8+ Aggressive
Epidermotropic Cytotoxic T-Cell Lymphoma
Since the ﬁrst description by Berti,114 less than 50 cases
of this rare and aggressive form of CD8+ CTCL have been
reported in the literature. The current diagnostic criteria for
CD8+ AECTCL include short history, widespread lesions,
epidermotropism of pleomorphic T cells, a CD8+/CD42 phe-
notype, and an aggressive course as essential diagnostic ele-
ments.115 This rare lymphoma shows predilection for men
(male:female ratio approximately 2:1), with most patients
being affected in their ﬁfth to seventh decade (age ranges at
diagnosis from 19 to 83 years). In typical cases, the disease
manifests with widespread erosive patches, plaques, or pap-
ules and nodules undergoing necrosis and ulceration114
(Fig. 13). Less common are hyperkeratotic patches and pla-
ques and annular lesions, but, recently, the occurrence of
pustules during disease course have also been described.116
CD8+ AECTCL shows a short history with rapidly progress-
ing skin lesions and spread to extracutaneous sites, particu-
larly oral mucosa, visceral organs (lung), and central nervous
system. The lymph nodes are usually not involved. The dis-
ease runs an aggressive course with a median survival of less
than 32 months and a 5-year survival rate of 18%.114,115 Only
a small subset of patients seems to have a less aggressive
course.117 Multiagent chemotherapy is not very effective
and followed by rapid relapse. Combination of chemotherapy
and autologous stem cell transplantation may be a promising
strategy to control the disease.115
A histological hallmark is prominent epidermotropism
of small–medium or medium–large lymphocytes with pleo-
morphic chromatin-dense nuclei (Fig. 14). Numerous apopto-
tic keratinocytes and spongiosis are common features. Blister
formation is occasionally seen. Extension of the lymphocytic
inﬁltrates into the deeper dermis and subcutis, angiocentric
growth, and destruction of adnexal structures may be seen but
are rare.
The tumor cells express CD3+, CD42 CD8+, CD45RA+,
CD45RO2, TIA-1+, and beta F1+.114,115,118 CD30 is typically
negative (E. Berti, MD, PhD personal communication, January
2013). There is no association with EBV.
CD8+ AECTCL has a broad differential diagnosis. CD8+
MF is also characterized by a band-like and epidermotropic
inﬁltrate but displays only very few or no necrotic keratino-
cytes and no epidermal necrosis. CD8+ MF is characterized
clinically by hyper- or hypopigmented patches and plaques
and often affects young patients. In contrast to CD8+
AECTCL, no erosions, necroses, or ulcerations are seen.
CD8+ MF has the same favorable prognosis as classic MF.119
Pagetoid reticulosis, which may express CD8 and CD30,
FIGURE 12. Primary cutaneous CD8+ small/medium-sized
LPD: expression of CD8 by the vast majority of the infiltrate
(magnification, ·20).
FIGURE 13. Primary cutaneous CD8+ aggressive epidermo-
tropic cytotoxic T-cell lymphoma: patches and plaques with
erosions and hemorrhagic crusts (by courtesy of Prof D. Metze,
Germany).
FIGURE 14. Primary cutaneous CD8+ aggressive epidermo-
tropic cytotoxic T-cell lymphoma: epidermotropism of
medium-sized lymphocytes with moderately chromatin-dense
pleomorphic nuclei (magnification, ·200).
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histologically closely imitates CD8+ AECTCL, but it is by
deﬁnition characterized by a solitary lesion and runs an indo-
lent course. Clinical manifestation with self-regressing and
recurrent papules and small nodules distinguishes the recently
described LYP type D from CD8+ AECTCL.64 Additionally,
lymphocytes in LYP type D express CD30 in 90% of the cases
and lack the expression of CD45RA.64,65 PLEVA with the
expression of CD8 represents a further challenging histological
differential diagnosis due to numerous necrotic keratinocytes
and epidermotropism.72 Lack of signiﬁcant nuclear atypia, and
the clinical presentation with scaly macules allow distinction of
PLEVA from CD8+ AECTCL.
Primary Cutaneous gamma/delta
T-Cell Lymphoma
CGD-TCL is a rare malignancy characterized by
a clonal proliferation of mature activated g/d T cells.101 The
g/d T cells represent a small subset (,5%) of all lymphocytes
found in the peripheral blood. These cells are essential part of
the innate immunity and play an important role in immuno-
surveillance. They express the g/d TCR and cytotoxic mole-
cules. Additionally, when activated, g/d T cells can express
1 or more NK-associated surface molecules (CD56, CD16,
and CD57), and in the activated stage, the cells become large
and granular.120 The g/d T cells are only exceptionally
encountered in cutaneous inﬂammatory and neoplastic lym-
phocytic inﬁltrates.121 Neoplastic proliferations of g/d T cells
comprise hepatosplenic and primary cutaneous forms.122,123
Approximately 100 cases of primary cutaneous g/d+
T-cell lymphoma have been reported to date. There are nei-
ther age nor gender predilection. Generalized often necrotic
or ulcerated papules, plaques, or nodules are seen clini-
cally.122,124 Involvement of oral mucosa is common and other
extranodal sites may become involved, but lymph nodes,
spleen, and bone marrow are usually spared. The patients
often have B symptoms. The disease may be accompanied
by a hemophagocytic syndrome, especially in patients with
the subcutaneous form of the disease.95,122,125 Hemophagocy-
tosis syndrome is deﬁned by fever, splenomegaly, cytopenia,
hypertriglyceridemia, and/or hypoﬁbrinogenemia, elevated
serum ferritin and CD25+ cells and evidence of hemophago-
cytic histiocytosis in bone marrow, spleen, or lymph nodes.126
It is accompanied by production of large amounts of inter-
feron gamma.95,127
Histologically, the disease manifests with the following
patterns: epidermotropic (pagetoid), dermal (diffuse or nod-
ular), and/or subcutaneous. An overlap is sometimes seen,
especially in the subcutaneous form, in which the predomi-
nantly subcutaneous inﬁltrates are often accompanied by
a dermal and an epidermotropic component.95,124 In the sub-
cutaneous forms, a predominantly lobular inﬁltrate composed
of medium- to large-sized with irregular chromatin-dense or
vesicular nuclei is observed (Fig. 15). Angioinvasion and
necrosis are common features.128 Immunophenotypically, the
tumor cells exhibit a CD2+, CD3+, CD56+ phenotype and are
often CD4/CD8 double negative. Cytotoxic molecules (TIA-1,
granzyme B, perforin) are typically expressed. In addition, the
expression of CD7 may be found. As the deﬁning criterion, the
neoplastic cells in primary CGD-TCL express TCR g/d (TCRd
+) and lack TCR a/b (betaF1). The g/d+ TCR phenotype can
be demonstrated by expression of TCR gamma on fresh-frozen
tissue or formalin-ﬁxed, parafﬁn-embedded sections or indi-
rectly by the lack of beta F1 expression. Molecular studies
reveal clonal rearrangement of TCR gamma or delta genes.
Isochromosome 7q is a common genetic abnormality. EBV
is generally negative, but isolated EBV+ cases of primary
CGD-TCL have been documented.129
Epidermotropic forms of primary CGD-TCL may
simulate MF and its subtype pagetoid reticulosis but expres-
sion of TCRg+ allows the correct diagnosis. This is also the
case for the subcutaneous form of g/d+ T-cell lymphoma that
should be distinguished from SPTCL. The latter expresses
a TCR a/b+ phenotype that is the main discriminating fea-
ture. Lymphocytic inﬁltrates in SPTCL are almost exclusively
restricted to the subcutis that is a helpful clue on histological
examination. The differential diagnosis of subcutaneous
gamma/delta T-cell lymphoma also includes extranodal NK/
T-cell lymphoma, nasal type. The latter is associated with
EBV and displays a CD3e+, CD56+ phenotype. However,
recently, an unusual case of a CD56+ CTCL exhibiting
immunophenotypic characteristics of both g/d T-cell lym-
phoma and extranodal NK/T-cell lymphoma, nasal type, has
been reported.130 The clinical course of primary CGD-TCL is
aggressive with a median survival of 15 months and a 5-year
survival rate of 33%.131 The lymphoma responds poorly to
multiagent chemotherapy, but hematopoietic stem cells trans-
plantation may provide a promising strategy.132 Remarkably,
few reports identiﬁed a less aggressive form of the disease
that can be controlled by ultraviolet light treatment in com-
bination with steroids, retinoids, or methotrexate.133,134
Cutaneous Peripheral T-Cell
Lymphoma, Unspecified/NOS
The terminology has been confusing and underwent
changes with each new lymphoma classiﬁcation. According
to the WHO-EORTC classiﬁcation and the current WHO
classiﬁcation, PTL, NOS represents a phenotypically and
FIGURE 15. Subcutaneous gamma/delta lymphoma. Sub-
cutaneous infiltrate of lymphocytes with atypical chromatin-
dense nuclei (magnification, ·200).
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prognostically heterogeneous group of CTCL that do not ﬁt
into any of the well-deﬁned CTCL subtypes. To date, only
very few case series and case reports have been documented
in the literature. PTL, NOS manifests with solitary,
grouped, or disseminated nodules without preceding
patches or plaques.106 PTL, NOS presenting with solitary
large ulceration has been described.135 Histologically, tu-
mors are characterized by diffuse or nodular dense inﬁl-
trates composed of variably sized, mostly medium- to
large-sized lymphoid cells with pleomorphic nuclei and
pale cytoplasm. Tumor cells may display an immunoblast-
like morphology (Fig. 16).106 Angiocentric inﬁltrates can be
observed. Epidermotropism has been reported as a feature
in a few cases.136 Eosinophils and plasma cells are ad-
mixed.137 Tumor cells exhibit a T-cell phenotype CD2,
CD3, and CD5 accompanied by loss of T-cell antigens such
as CD7. Tumor cells in PTL, NOS may be CD4 or CD8+ or
CD82. Cytotoxic phenotypes have been reported.135,136,138
By deﬁnition, the majority of tumor cells does not express
CD30.1 Molecular biologic assays reveal a clonal rearrange-
ment of TCR genes.
The differential diagnosis of PTL, NOS primarily
includes transformation of MF. Clinical presentation with
patches and plaques preceding transformation distinguishes
MF from PTL, NOS. Secondary cutaneous involvement by
nodal PTL has to be excluded by staging examinations.
Primary or secondary cutaneous ALCL is deﬁned by the
expression of CD30 by at least 75% of tumor cells, whereas
in PTL, NOS, the expression of CD30 is absent or restricted
to less than 30% of the tumor cells. The phenotype of
neoplastic cells allows differentiating PTL, NOS from extra-
nodal NK/T-cell lymphoma (CD3e+, CD56+, and association
with EBV) and g/d T-cell lymphoma (TCRg+). Especially in
patients of Asian origin or from the Caribbean region, HTLV-
1– or HTLV-2–associated adult T-cell lymphoma/leukemia
has to be distinguished by serology and/or molecular studies
demonstrating integration of the virus into the host genome of
tumor cells.
The prognosis of PTL, NOS is poor with a 5-year
survival rate of less than 20%.1,106,139 Complete remission
after chemotherapy and radiotherapy are usually of short
duration and followed by relapses.106 Patients with solitary
or localized skin lesions rapidly develop widespread disease.
Recent molecular studies revealed differences in chromo-
somal alterations, the expression of chemokine receptors,
and apoptosis regulators between PTL, NOS and primary
cutaneous ALCL that may account for the aggressive course
of PTL, NOS.94
Extranodal NK/T-Cell Lymphoma,
Nasal-Type, and Related Conditions
Extranodal NK/T-cell lymphoma, nasal type, is a rare
aggressive form of primary CL that shares immunopheno-
typical characteristics with normal NK cells and characteris-
tically displays a strong expression of CD56 and cytotoxic
proteins such as perforin, granzyme B, or TIA-1.140,141 The
TCR/CD3 complex is not expressed on the surface. Clonal
episomal presence of EBV is typically found. TCR genes are
usually in germline conﬁguration. Histology shows dense
diffuse inﬁltrates (Fig. 17). Angiocentric and angiodestructive
growth resulting in necroses and ulceration is often found.
The tumor cells are of variable size ranging from small to
large cells with pleomorphic nuclei and pale cytoplasms.
Mitoses are common. Occasionally, numerous admixed reac-
tive cells such as eosinophils, plasma cells, and histiocytes are
observed. Extranodal NK/T-cell lymphoma may be associated
with pseudoepitheliomatous hyperplasia.
Hydroa vacciniformia–like lymphoma is a rare variant
of EBV+ NK/T-cell lymphoma mostly seen in the Central and
South America. The disease shows predilection for young
adults and children and commonly involves sun-exposed areas
where rapid progression from edema to blisters and ulcers and,
ﬁnally, scarring is observed.142,143 Facial swelling is a typical
feature. Extracutaneous symptoms such as fever, hepatosple-
nomegaly, lymphadenopathy, and an increased high lactate
dehydrogenase (LDH) level can occur. Often, the disease fol-
lows a protracted course, eventually leading to an aggressive
phase characterized by concurrent infections and disease
FIGURE 16. Peripheral T-cell lymphoma, not otherwise spec-
ified: cohesive infiltrates of large lymphoid cells with nuclear
pleomorphism. Some of the tumor cells have an immunoblast-
like cytomorphology (magnification, ·400).
FIGURE 17. Extranodal NK/T-cell lymphoma: infiltrates of
small- to medium-sized lymphocytes with chromatin-dense
nuclei. Note central necrosis (magnification, ·100).
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progression. In a recent series from Peru, 10 of 14 patients died
after a mean follow-up of 11.6 months.144 There have been few
reports in the recent literature on cutaneous EBV+ NK/T-cell
lymphoid proliferations that were different—either phenotypi-
cally or by showing an unusual clinical course—from both
classic extranodal NK/T-cell lymphoma, nasal type, and hy-
droa vacciniformia–like lymphoma, suggesting that the spec-
trum of these conditions might be broader.145,146
Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
had traditionally been included in CL classiﬁcations under
designations blastic NK-cell lymphoma and agranular CD4+
CD56+ hematodermic neoplasm. This neoplasm, however, is
derived from plasmacytoid dendritic cells,147,148 hence its name
BPDCN. The disease usually presents with rapidly evolving
disseminated contusiform or bruise-like patches and plaques.
Manifestation with a solitary skin lesion is rare. Involvement of
the oral mucosa is common. Leukemic involvement may be or
may be not present at the time of the occurrence of skin lesions
but occurs in 70% of the patients during disease course.147
Histologically, there is a diffuse or multinodular monot-
onous inﬁltrate, which sometimes is bandlike in the upper and
mid dermis with column-like extensions into the deeper dermis
and subcutis. The tumor cells resemble blasts with ﬁne-
dispersed chromatin. Spilling between collagen bundles is
sometimes seen at the periphery of the inﬁltrate. Extensive
intratumoral erythrocyte extravasation is usually found between
the tumor cells, which account for the characteristic clinical
contusiform aspect. In initial lesions, a perivascular inﬁltrate can
be observed that may be mistaken as an inﬂammatory skin
disorder such as erythema annulare centrifugum or drug
eruption (Figs. 18 and 19).
Immunophenotypically, the neoplastic cells displays
a unique phenotype with the expression of CD4, CD56,
CD123, and TCL-1.147 TdT is variably expressed. Recently,
new antibodies recognizing PDC-related antigens and work-
ing on parafﬁn sections became available, namely BDCA-2,
BCL11a, and CD2AP.
The data on genetics of this neoplasm are scarce.
Recently, genetic alterations involving chromosomes 5, 6, 9,
12, 13, and 15 have been identiﬁed using array comparative
genomic hybridization conﬁrmed by ﬂuorescence in situ
hybridization analysis, but no speciﬁc genetic marker has
been found.149 The above study has also conﬁrmed the capa-
bility of the neoplastic cells to secrete interferon-1, demon-
strated by biologic interferon-1 activity of cultured cells and
immunohistochemical expression ofMx-1 protein.149 In a series
of 21 cases studied by array comparative genomic hybridiza-
tion, complete or partial chromosomal losses largely outnum-
bered the gains, with common deleted regions involving
9p21.3 (CDKN2A/CDKN2B), 13q13.1-q14.3 (RB1),
12p13.2-p13.1 (CDKN1B), 13q11-q12 (LATS2), and 7p12.2
(IKZF1) regions. Biallelic loss of locus 9p21.3 was statistically
signiﬁcant for a lower survival.150
This dendritic cell neoplasm is associated with a poor
prognosis.147,148 In some patients, the disease develops in the
context of myelodysplastic syndrome or has been associated
with chronic monomyelocytic leukemia.151 The distinction of
BPDCN from the latter may be challenging for 2 reasons.
First, a dermal inﬁltrate of plasmacytoid dendritic cells may
occasionally occur in a patient suffering from a myeloid neo-
plasm, a phenomenon poorly understood at present.152 Second,
chronic monomyelocytic leukemia seems to be a heterogeneous
disorder with a subtype similar if not identical to BPDCN.153
The concomitant occurrence of cutaneous BPDCN and cuta-
neous B-cell LPD has been reported indicating that BPDCN
may be associated with lymphoid neoplasms.154 This article
provides an overview of the spectrum of cutaneous T- and
NK/T-cell lymphomas including recently identiﬁed new mor-
phologic and phenotypic variants of these lymphomas and
discusses diagnostic and prognostic markers in indolent and
aggressive forms of cutaneous T-cell lymphomas.
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After completing this CME activity, physicians should be better able to describe the morphologic and phenotypic spectrum
of cutaneous T-cell lymphomas, identify new variants of cutaneous T-cell lymphomas, especially in mycosis fungoides and
cutaneous CD30-positive lymphoproliferative disorders, and distinguish indolent forms of cutaneous T-cell lymphomas from
aggressive forms.
1. Which statement on mycosis fungoides (MF) is true?
a) MF with a CD8-positive phenotype carries a poor prognosis.
b) Unilesional MF most commonly displays a CD8-positive phenotype.
c) Folliculotropic and granulomatous MF have an impaired prognosis.
d) B-cells are consistently absent in early MF and serve as a diagnostic marker to distinguish MF from inﬂammatory disorders.
2. A patient presents with erythroderma, peripheral lymphadenopathy, palmar and plantar keratosis, and loss of pubic and
axillary hairs. What is the most likely diagnosis?
a) Psoriatic erythroderma
b) Sezary syndrome
c) Acute T-lymphoblastic lymphoma/leukemia
d) Actinic reticuloid
3. Which statement regarding primary cutaneous CD30+ anaplastic large cell lymphoma (ALCL) is true?
a) ALCL most commonly presents with multiple nodules with predilection for the extremities.
b) By deﬁnition, 50% of the tumor cells have to express CD30.
c) Primary cutaneous ALCL usually lacks the translocation t(2;5).
d) Expression of CD8 by the tumor cells is associated with a poor prognosis.
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4. Subcutaneous panniculitis-like T-cell lymphoma has, in general, a very good prognosis (5-year survival . 80%). To
distinguish it from more aggressive variants of subcutaneous gamma/delta T-cell lymphoma, it is pivotal to demonstrate:
a) Clusters of CD123 positive cells
b) BetaF1 positive phenotype
c) Angiocentric growth pattern
d) EBV positivity
5. Which statement is correct?
a) Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma typically lacks expression of CD45RA.
b) Cutaneous gamma delta T-cell lymphoma is associated with Epstein Barr virus in the majority of cases.
c) Tumor cells in subcutaneous panniculitis like T-cell lymphoma usually express CD4 and CD56.
d) The CD4+ T-cells in primary cutaneous CD4-positive small/medium T-cell lymphoma express PD-1.
6. The neoplastic cells in blastic neoplasm of plasmacytoid dendritic cells, which is derived from plasmacytoid dendritic cells,
display a speciﬁc phenotype Which combination of markers is typically expressed by the tumor cells?
a) CD8, TIA-1, CD123, TCL-1
b) CD3, CD21, CD79a, CD123
c) CD7, CD56, CD123, EBV
d) CD4, CD56, CD123, TCL-1
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